Patriot Investment Management Group Inc. Sells 1,428 Shares of Pfizer Inc. (NYSE:PFE)

Patriot Investment Management Group Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,321 shares of the biopharmaceutical company’s stock after selling 1,428 shares during the period. Patriot Investment Management Group Inc.’s holdings in Pfizer were worth $460,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Fred Alger Management LLC grew its position in Pfizer by 6.6% in the second quarter. Fred Alger Management LLC now owns 95,592 shares of the biopharmaceutical company’s stock valued at $2,675,000 after acquiring an additional 5,932 shares during the last quarter. Caxton Associates LP acquired a new stake in shares of Pfizer during the 2nd quarter valued at $738,000. AXA S.A. increased its holdings in Pfizer by 4.9% in the 2nd quarter. AXA S.A. now owns 2,632,380 shares of the biopharmaceutical company’s stock worth $73,654,000 after purchasing an additional 123,605 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after purchasing an additional 9,435 shares in the last quarter. Finally, Drucker Wealth 3.0 LLC bought a new position in Pfizer in the 2nd quarter valued at approximately $2,782,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Stock Up 1.7 %

Shares of NYSE:PFE opened at $26.46 on Friday. The company has a market cap of $149.94 billion, a price-to-earnings ratio of 35.75, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a fifty day moving average price of $26.07 and a two-hundred day moving average price of $27.96. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the business earned ($0.17) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.50%. Pfizer’s payout ratio is presently 227.03%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.